异黄酮干预对绝经后女性骨密度的影响:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入63项随机对照试验(异黄酮组4754例、安慰剂组4272例),评估异黄酮干预对绝经后女性骨密度的影响。结果显示异黄酮干预显著改善腰椎、股骨颈和桡骨远端骨密度,亚组分析显示疗程≥12个月且含染料木黄酮至少50 mg/天的干预有效。结论提示含染料木黄酮至少50 mg/天的异黄酮干预可有效提升绝经后女性骨密度。
要点
- 异黄酮干预显著改善绝经后女性腰椎骨密度(MD=0.0175 g/cm2,95%CI 0.0088至0.0263,P<0.0001)。
- 异黄酮干预显著改善股骨颈骨密度(MD=0.0172 g/cm2,95%CI 0.0046至0.0298,P=0.0073)。
- 疗程≥12个月且含染料木黄酮至少50 mg/天的异黄酮干预对改善骨密度有效。
核心结论
- 该系统综述与Meta分析提示,异黄酮干预尤其是含染料木黄酮至少50 mg/天的干预,可有效提升绝经后女性骨密度。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Scopus和Cochrane Library数据库至2023年4月20日。
- 纳入63项随机对照试验,异黄酮干预组4754例、安慰剂组4272例。
- 采用随机效应模型,以均数差(MD)及95%置信区间(CI)为效应量汇总指标,并使用RoB2工具评估偏倚风险。
主要发现
- 异黄酮干预显著改善腰椎骨密度(MD=0.0175 g/cm2,95%CI 0.0088至0.0263,P<0.0001)。
- 异黄酮干预显著改善股骨颈骨密度(MD=0.0172 g/cm2,95%CI 0.0046至0.0298,P=0.0073)。
- 异黄酮干预显著改善桡骨远端骨密度(MD=0.0138 g/cm2,95%CI 0.0077至0.0198,P<0.0001)。
- 亚组分析显示,疗程≥12个月且干预含染料木黄酮至少50 mg/天时,异黄酮干预对改善骨密度有效。
关键数值与推荐
- 腰椎骨密度:异黄酮组较安慰剂组MD=0.0175 g/cm2(95%CI 0.0088至0.0263,P<0.0001)。
- 股骨颈骨密度:异黄酮组较安慰剂组MD=0.0172 g/cm2(95%CI 0.0046至0.0298,P=0.0073)。
- 桡骨远端骨密度:异黄酮组较安慰剂组MD=0.0138 g/cm2(95%CI 0.0077至0.0198,P<0.0001)。
- 亚组分析中有效干预的条件为疗程≥12个月且含染料木黄酮至少50 mg/天。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Due to estrogen deficiency, postmenopausal women may suffer from an imbalance in bone metabolism that leads to bone fractures. Isoflavones, a type of phytoestrogen, have been suggested to improve bone metabolism and increase bone mass. Therefore, isoflavones are increasingly recognized as a promising natural alternative to hormone replacement therapy for postmenopausal women who face a heightened risk of osteoporosis and are susceptible to bone fractures. PURPOSE: This study aimed to evaluate the efficacy of isoflavone interventions on bone mineral density (BMD) in postmenopausal women by means of systematic review and meta-analysis. METHODS: The electronic database searches were performed on PubMed, Embase, Scopus, and Cochrane Library databases, covering literature up to April 20, 2023. A random-effects model was used to obtain the main effect estimates, with a mean difference (MD) and its 95% confidence interval (CI) as the effect size summary. The risk of bias assessment was conducted using the Risk of Bias 2 (RoB2) tool. RESULTS: A total of 63 randomized controlled trials comparing isoflavone interventions (n = 4,754) and placebo (n = 4,272) were included. The results indicated that isoflavone interventions significantly improved BMD at the lumbar spine (MD = 0.0175 g/cm2; 95% CI, 0.0088 to 0.0263, P < 0.0001), femoral neck (MD = 0.0172 g/cm2; 95% CI, 0.0046 to 0.0298, P = 0.0073), and distal radius (MD = 0.0138 g/cm2; 95% CI, 0.0077 to 0.0198, P < 0.0001) in postmenopausal women. Subgroup analysis showed that the isoflavone intervention was effective for improving BMD when the duration was ≥ 12 months and when the intervention contained genistein of at least 50 mg/day. CONCLUSION: This systematic review and meta-analysis suggests that isoflavone interventions, especially those containing genistein of at least 50 mg/day, can effectively enhance BMD in postmenopausal women.
引用
- Inpan R, Na Takuathung M, Sakuludomkan W, et al. Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2023. PMID: 37875614. doi:10.1007/s00198-023-06944-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。